acuteadultsadvancedallogeneicamlasctavdaxicabtagenebestbonebortezomibcarecellchronicciloleucelclassiccomparedcontrolledcyclophosphamidecytarabinedaratumumabdecitabinedexamethasonediagnoseddiffusediseasedonordonorsdosedoubleduplicationdurationfirstfixedflt3followgilteritinibgraftguidedhaploidenticalhematopoietichighhlahodgkinhosthsctibrutinibiiiiiimmunochemotherapyinductioninternallabellargelenalidomideleukemialonglowlymphoblasticlymphocyticlymphomamaintenancemantlemarrowmatchedmethotrexatemrdmulticentermulticentremultiplemutationmycophenolatemyelodysplasticmyeloidmyelomanewlynivolumabolderopenoraloutcomespatientsphaseplacebopluspomalidomidepostposttransplantposttransplantationpreventionprophylacticprophylaxisptcyrandomisedrandomizedreducedrefractoryrelapsedremissionresidualresultsriskrituximabstagestandardstemstudysubcutaneoussyndrometacrolimustandemtermtherapytransplanttransplantationtreatedtrialunrelateduntreatedvenetoclaxversuswithoutzanubrutinib